0
Atara Biotherapeutics Inc Banner Image

Atara Biotherapeutics Inc

  • Ticker ATRA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Atara Biotherapeutics Inc Logo Image
  • 201-500 Employees
  • Based in South San Francisco, California
Atara Biotherapeutics Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory and manufacturing expertise. Atara’s pipeline includes tab-celMore® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California.
Atara Biotherapeutics Inc

Most Recent Annual Report

Atara Biotherapeutics Inc MOST RECENT 2019 Annual Report and Form 10K

Older/Archived Annual Reports